Califf Urges Congressional Patience On Opioid Actions
Executive Summary
Labeling changes for the pain products remain in active discussion, the US FDA commissioner tells the Senate Health, Education, Labor and Pensions Committee during a hearing on the monkeypox outbreak.
You may also be interested in...
Califf Hints At Labeling Changes For Opioids And Chronic Pain
Califf also said the agency is open to endpoints other than abstinence for new opioid use disorder treatments at the fourth annual NIH HEAL Initiative Investigator Meeting.
‘Opioids’ Is Missing From The US FDA’s Overdose Prevention Framework Title On Purpose
Unlike prior plans, the FDA’s new substance abuse framework is intended to deal with stimulant and benzodiazepine use disorders, in addition to opioid abuse.
New Opioid Approval Standard Intended To Drive Development Into Other Therapeutics
US FDA explored whether existing law allowed for the higher standard, but determined new authority granted by Congress was necessary.